Business
Kneat Signs Global Biotechnology Leader
Kneat Signs Global Biotechnology Leader Canada NewsWire HALIFAX, March 11, 2019 ...
About this update from Kneat.com, Inc.
[{"type":"text","content":"\n\n\n\nKneat Signs Global Biotechnology Leader\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nHALIFAX, March 11, 2019\n\n\n\nHALIFAX, March 11, 2019 /CNW/ - kneat.com, inc. (TSXV: KSI) (\"Kneat\") is pleased to announce that an international leader in biotechnology has chosen Kneat's software platform to facilitate its transition to paperless validation processes.  With over 20,000 employees globally and manufacturing facilities in four continents, this company develops innovative therapies for patients around the world.  Kneat's platform will initially be launched for facilities, utilities and equipment commissioning and qualification (\"C&Q\") at a manufacturing plant in the United States.\n\n \n \n\n \n\"We look forward to working closely with this customer to convert their current paper C&Q process to an end-to-end digital process,\" said Eddie Ryan, Chief Executive Officer of Kneat. \"C&Q is one of many processes that can be fully digitized on the Kneat platform, allowing our customers to experience meaningful productivity gains and cost savings while maintaining their high compliance standards.\"\nKneat continues to expand its customer pipeline and will report on further developments as they occur.\nAbout Kneat\nKneat develops and markets the next generation Kneat Gx software platform.  Multiple business processes can be configured on the platform from equipment to computer system validation, through to quality document management.  Kneat's software allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform.  Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide.  Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard.  For more information visit www.kneat.com.\nCautionary and Forward-Looking Statements\nExcept for the statements o...